Adaptive Biotechnologies struck two non‑exclusive agreements with Pfizer: one to apply Adaptive’s T‑cell receptor (TCR) discovery platform to Pfizer clinical samples for rheumatoid arthritis target identification, and another multi‑year data access license for Adaptive’s TCR‑antigen mapping datasets to train AI/ML models. Adaptive will receive an upfront payment and may earn up to roughly $890 million in milestone and commercial payments under the arrangements. Pfizer gains both target discovery capabilities and large‑scale immune receptor data to accelerate discovery and translational efforts across disease areas. The deals underscore the growing value of immune‑receptor datasets and AI‑enabled target identification in immunology drug development.